IPO - FEMASYS INC

Form Type: 424B5

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000114036125021029

Filing Summary: Femasys Inc. is offering 3,600,000 shares of its common stock at a price of $0.85 per share, raising a total of $3,060,000. As of May 28, 2025, the last sale price of the company's common stock was $1.06, reflecting significant interest in its stock. The underwriting discount is set at $0.0595 per share, totaling $214,200. The proceeds, before expenses, are estimated at $2,845,800. The company intends to grant an underwriter an option to purchase an additional 540,000 shares in the next 30 days. Approximately $33.0 million is the market value of the outstanding common stock held by non-affiliates, based on 25,551,370 shares. A concurrent private placement will see institutional stockholders and certain officers purchasing 1,588,235 shares at $0.85 and 98,040 shares at $1.02, respectively. The offering is planned to close on or around June 2, 2025. Immediate risks and uncertainties include compliance with Nasdaq listing rules and regaining minimum market value compliance by November 17, 2025, given potential delisting risks. The company has ongoing innovative developments in women's healthcare products, especially in permanent birth control, with significant market potential and various regulatory approvals worldwide.

Form Type: 8-K

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000114036125021030

Filing Summary: On May 29, 2025, Femasys Inc. entered into an underwriting agreement with JonesTrading Institutional Services LLC for a public offering of 3,600,000 shares of common stock at a price of $0.85 per share. Additionally, a 30-day option was granted to purchase up to 540,000 shares more. The offering is registered under an effective shelf registration statement. Concurrently, Femasys entered into a Stock Purchase Agreement with institutional stockholders and certain directors to sell an aggregate of 1,686,275 shares at $0.85 and $1.02 per share respectively. The gross proceeds from these transactions are expected to total $4.5 million. The net proceeds are slated for expanding commercial efforts, product development, and general corporate purposes. The closing of these transactions is scheduled for June 2, 2025. Furthermore, an equity line of credit agreement is expected with Alumni Capital LP for $10 million, to be finalized by June 30, 2025, with a provision for liquidated damages if not completed on time.

Form Type: 424B5

Filing Date: 2025-05-29

Corporate Action: Ipo

Type: New

Accession Number: 000114036125020782

Filing Summary: Femasys Inc. is offering shares of common stock at a purchase price to be determined. The common stock is listed on the Nasdaq Capital Market under the symbol 'FEMY.' The last reported sale price on May 28, 2025, was $1.06 per share. This offering includes underwriting discounts of 7% on gross proceeds. A concurrent private placement is anticipated with institutional stockholders and certain company officers purchasing shares at the same public offering price. The offering is not contingent on the private placement and vice versa. Femasys is noted for its innovative products in women's health, specifically its FemBloc permanent birth control system, which has received regulatory approvals and is being commercialized in both U.S. and international markets. The company recently experienced Nasdaq notice for minimum listing requirements but continues to monitor its situation until November 2025. New equity lines may also be established to secure additional funding. There is a caution regarding forward-looking statements within the prospectus.